jakhals schreef op 12 december 2017 13:47:
[...]11/29/2017
C1-Esterase Inhibitor (Human) Injection
Products Affected - Description
Berinert intravenous injection, CSL Behring
500 unit, preservative-free vial (NDC 63833-0825-02)
Cinryze intravenous injection, Shire
500 unit, preservative-free vial (NDC 42227-0081-05)
Reason for the Shortage
CSL Behring has limited supply of Berinert due to increased demand.Shire has resumed manufacturing of Cinryze and certain lots are available.The subcutaneous dosage form of C1-esterase inhibitor (human) is unaffected by this shortage.
Available Products
There is insufficient supply for usual ordering
Estimated Resupply Dates
CSL Behring is shipping limited supplies of Berinert to specialty distributers.Shire has certain lots of Cinryze available.
Implications for Patient Care
The following lots require filtering prior to administering: 17F19L37OA, 17F24L370A, 17G10L370A, 17G16L370A, 17G21L370A, 17H12L370A, 17G26L370A and 17H22L370A. Additional information and self-administration instructions are available.
Updated
November 29, October 11 and 4, September 13, August 16, 2017, University of Utah, Drug Information Service. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.